Brain-machine interface (BMI) technology has gained significant attention due to Elon Musk's Neuralink. In the secondary market, the BMI sector has seen a resurgence in prices. Institutions predict that the market size related to brain-machine interfaces could reach between $70 billion and $200 billion from 2030 to 2040.

The term "brain-machine interface" refers to the direct connection established between the human or animal brain and external devices, allowing for information exchange between the brain and these devices. Traditionally, human interaction with external devices relies on the peripheral nervous and muscular systems; however, brain-machine interfaces enable direct control of external devices by interpreting brain activity. If this technology matures, it holds the potential to address many neurodegenerative diseases, including Alzheimer's, blindness, paralysis, and brain injuries, providing hope for restoring sensory and motor functions.

Brain engineering involves developing information and computing technology platforms that can achieve neuroinformatics, brain simulation, and supercomputing. This aims to aggregate neuroscience data from around the world into a unified model to simulate the human brain, compare biological data, and share resources with the global scientific community.

What Are Some Notable Stocks Related to Brain Engineering Concepts?

International Brain Science Concept Stocks:

Neuralink: A brain-machine interface company founded by Elon Musk, widely covered for its technological advancements.

Synchron: Another well-known brain-machine interface company whose products have received FDA approval for human trials.

Abbott: A large medical device company that has made strides in the field of neuroscience.

Medtronic: A leading global medical technology company with a robust product line in neural modulation.

As leading international firms, their progress and movements often guide industry trends and create a demonstration effect on related domestic companies.

Domestic Brain Science Concept Stocks:

Innovative Medical: This company has been a leader in the brain-machine interface field, achieving significant clinical application progress.

Sanbo Neuroscience: Focused on the diagnosis and treatment of brain diseases, also venturing into neural modulation.

Boji Pharmaceutical: Has a product line in neural modulation and a solid technical foundation in the field.

Fudan Forward: One of the earlier players in brain disease treatment, with a diverse product line.

iFLYTEK: Primarily engaged in artificial intelligence, but has also made inroads into brain-machine interfaces, establishing a joint laboratory with South China University of Technology.

Century Huatong and Talking Tom: Although their main businesses are not in healthcare, they have made some investments in the brain science field.

Beilu Pharmaceutical and Rejing Biotechnology: These companies have made progress in drug development for neurological diseases.

These companies are well-known and influential in the domestic brain science field, holding a first-mover advantage in technology development and product launches.

For stocks of this conceptual type, we can pay attention to leading stocks and those with favorable trend patterns. Of course, if there has been a significant short-term increase, it's essential to be cautious of risks; stocks that are recovering from the bottom are also a good option. Those interested can conduct in-depth research on the financial performance, operational status, and shareholder information of the related listed companies.

Follow us

Find us on Twitter, Instagram, YouTube, and TikTok for frequent updates on all things investing.

Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！

Important Notice and Disclaimer:

We have based this article on our internal research and information available to the public from sources we believe to be reliable. While we have taken all reasonable care in preparing this article, we do not represent the information contained in this article is accurate or complete and we accept no responsibility for errors of fact or for any opinion expressed in this article. Opinions, projections and estimates reflect our assessments as of the article date and are subject to change. We have no obligation to notify you or anyone of any such change. You must make your own independent judgment with respect to any matter contained in this article. Neither we or our respective directors, officers or employees will be responsible for any losses or damages which any person may suffer or incur as a result of relying upon anything stated or omitted from this article.

This document should not be construed in any jurisdiction as constituting an offer, solicitation, recommendation, inducement, endorsement, opinion, or guarantee to purchase, sell, or trade any securities, financial products, or instruments or to engage in any investment or any transaction of any kind, nor is there any intention to solicit or invite the purchase or sale of any securities.

The value of these securities and the income from them may fall or rise. Your investment is subject to investment risk, including loss of income and capital invested. Past performance figures as well as any projection or forecast used in this article is not indicative of its future performance.

This advertisement has not been reviewed by the Monetary Authority of Singapore